|
|
| (7 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Esmolol#Contraindications]] |
| {{Esmolol}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
| | |
| ==Contraindications==
| |
| | |
| BREVIBLOC (Esmolol Hydrochloride) is '''contraindicated''' in patients with:
| |
| | |
| :*'''Severe [[sinus bradycardia]]''': May precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest .
| |
| :*'''[[Heart block]]''' greater than first degree: Second- or third-degree [[atrioventricular block]] may precipitate or worsen [[bradycardia]] resulting in cardiogenic shock
| |
| :*'''[[cardiac arrest]]''' .
| |
| :*'''[[Sick sinus syndrome]]''': May precipitate or worsen bradycardia resulting in [[cardiogenic shock]] and [[cardiac arrest]]
| |
| :*'''Decompensated [[heart failure]]''': May worsen [[heart failure]].
| |
| :*'''[[Cardiogenic shock]]''': May precipitate further cardiovascular collapse and cause [[cardiac arrest]].
| |
| :*'''IV administration of cardiodepressant''' [[calcium-channel antagonists]] (e.g., verapamil) and BREVIBLOC in close proximity (i.e., while cardiac effects from the other are still present); fatal cardiac arrests have occurred in patients receiving BREVIBLOC and intravenous verapamil.
| |
| :*'''[[Pulmonary hypertension]]''': May precipitate cardiorespiratory compromise.
| |
| :*'''[[Hypersensitivity reactions]]''', including [[anaphylaxis]], to esmolol or any of the inactive ingredients of the product ([[cross-sensitivity]] between beta blockers is possible).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BREVIBLOC (ESMOLOL HYDROCHLORIDE) INJECTION [BAXTER HEALTHCARE CORPORATION] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=595cc3d5-1306-4828-aefa-5595219ffd62 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
|
| |
|
| | [[Category:Beta blockers]] |
| | [[Category:Cardiovascular Drugs]] |
| [[Category:Drugs]] | | [[Category:Drugs]] |